Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | GRIN2B | Q13224 | 8/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | F13A1 | P00488 | 1/20 | 0.53 |
| ▸ | TGM2 | P21980 | 1/20 | 0.53 |
| ▸ | TGM1 | P22735 | 1/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2515606 | 0.99 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL16343926 | 0.99 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL15669761 | 0.92 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL3086491 | 0.87 | SMN1; SMN2 (0.70) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL8621729 | 0.87 | SMN1; SMN2 (0.63) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL27417332 | 0.86 | SMN1; SMN2 (0.70) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL26510676 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL1780742 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| SCHEMBL9241437 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 | |
| Hydrochloric Acid SCHEMBL3320885 | 0.85 | SMN1; SMN2 (0.67) | SMN1; SMN2CYP2C19NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250270213-A1 | PI3Ka INHIBITORS | PIKAVATION THERAPEUTICS, INC. | 2025-08-28 | — | — | US | disclosed |
| CN-119654321-A | PI3K alpha inhibitors | 突触活化疗法股份有限公司 | 2025-03-18 | — | — | CN | disclosed |
| EP-4511373-A1 | PI3K? INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2025-02-26 | — | — | EP | disclosed |
| CN-115151550-B | External nucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2024-11-22 | — | — | CN | disclosed |
| CN-116496283-B | Pentaaza acenaphthene compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023205680-A1 | PI3Kα INHIBITORS | SYNNOVATION THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| CN-116496283-A | Pentaaza acenaphthene compound, preparation method, pharmaceutical composition and application | 中国药科大学 | 2023-07-28 | — | — | CN | disclosed |
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2023-04-20 | — | — | US | disclosed |
| EP-4081528-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | Sanford Burnham Prebys Medical Discovery Institute (US) | 2022-11-02 | — | — | EP | disclosed |
| CN-115151550-A | Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP 1) modulators and uses thereof | 桑福德·伯纳姆·普雷比医学发现研究所 | 2022-10-04 | — | — | CN | disclosed |
| WO-2008137436-A1 | [6,5]-BICYCLIC GPR119 G PROTEIN-COUPLED RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-13 | — | — | WO | disclosed |
| WO-2008104077-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | METHYLGENE INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
| WO-2008104077-A1 | SMALL MOLECULE INHIBITORS OF PROTEIN ARGININE METHYLTRANSFERASES (PRMTS) | METHYLGENE INC. (CA) | 2008-09-04 | — | — | WO | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217714-B1 | CCR5 modulators | AGOURON PHARMACEUTICALS, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| CN-1150192-C | Piperidines as CCR5 modulators | — | 2004-05-19 | — | — | CN | disclosed |
| CN-1331691-A | Piperidines as CCR5 modulators | PFIZER LTD (US) | 2002-01-16 | — | — | CN | disclosed |
| EP-1140920-A1 | PIPERIDINES AS CCR5 MODULATORS | Pfizer Limited (GB) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000039125-A1 | PIPERIDINES AS CCR5 MODULATORS | PFIZER LIMITED (GB) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230121698-A1 | ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) MODULATORS AND USES THEREOF | ENPP1, ENPP3, PPA1 | SMN1; SMN2 3049/4885CYP2C19 3990/4885NPC1 2739/4885 |
| US-20250270213-A1 | PI3Ka INHIBITORS | PIK3CA, PIK3C2A, PIK3R5 | SMN1; SMN2 1804/4885CYP2C19 4482/4885NPC1 701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.